GLPwatch
Papers (12034)
Page 96 of 201, ranked by citation count.
- Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.
- Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
- Contractile Effects of Semaglutide in the Human Atrium.
- Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example.
- Change in HbA<sub>1c</sub> Across the Baseline HbA<sub>1c</sub> Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.
- A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity.
- Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes.
- Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4.
- Liraglutide-Induced Pancreatitis: A Case Report and Literature Review.
- Surface-mediated spontaneous emulsification of the acylated peptide, semaglutide.
- Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial.
- Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues.
- Editorial: Global Obesity Rates Continue to Rise with Challenges for New Drug Treatments Including GLP-1 Receptor Agonists.
- Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice.
- Semaglutide improves metabolic dysfunction-associated steatohepatitis: A 10-year retrospective study.
- Synthesis and pharmaceutical characterization of site specific mycophenolic acid-modified <i>Xenopus</i> glucagon-like peptide-1 analogs.
- The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials.
- Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis.
- The Effect of Liraglutide on Axon Regeneration and Functional Recovery after Peripheral Nerve Lesion.
- SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination.
- Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
- Successful Implementation of a Multidisciplinary Weight Loss Program Including GLP1 Receptor Agonists for Liver Transplant Candidates With High Body Mass Index.
- Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.
- The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.
- Sustained Weight Loss With Combined LEAP2 and Semaglutide Treatment in Mice.
- A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
- Anaphylaxis to Long-Acting Release Exenatide.
- Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
- Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity.
- Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
- A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.
- Vertical sleeve gastrectomy and semaglutide have distinct effects on skeletal health and heart function in obese male mice.
- Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
- Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
- An unusual case of a generalised cutaneous drug reaction to liraglutide.
- Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis.
- Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide.
- Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells.
- Cardiovascular Outcome Trials with Glucose-Lowering Drugs.
- Dulaglutide for the treatment of type 2 diabetes.
- The comparison of three different molecular imaging methods in localization and grading of insulinoma.
- PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats.
- Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.
- GLP-1 agonists to slow down Parkinson's progression? The quest continues.
- Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease.
- Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability.
- Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.
- Sphingosine kinase 1-interacting protein is a novel regulator of glucose-stimulated insulin secretion.
- Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
- Induction of insulin-producing cells from human pancreatic progenitor cells.
- Appetite suppressant semaglutide is to be made available to treat obesity in England.
- Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease.
- Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review.
- Mechanisms and treatment of obesity-related hypertension-Part 2: Treatments.
- Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice.
- Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.
- GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.
- Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.
- Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.
- Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.